[CAS NO. 676128-63-5] RSV604

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [676128-63-5]

Catalog

HY-12993

Brand

MCE

CAS

676128-63-5

DESCRIPTION [676128-63-5]

Overview

MDL	-
Molecular Weight	388.39
Molecular Formula	C22H17FN4O2
SMILES	O=C1[C@@H](NC(NC2=C(F)C=CC=C2)=O)N=C(C3=CC=CC=C3)C4=CC=CC=C4N1

For research use only. We do not sell to patients.

2 Publications Citing Use of MCE

Summary

RSV604 (A-60444) is an inhibitor of respiratory syncytial virus (RSV) replication. RSV604 targets the nucleocapsid protein , with a K _d of 1.6 μM. RSV604 displays submicromolar activity against numerous clinical isolates of both the A and B subtypes of RSV (average EC ₅₀ s=0.8 μM) ^[1] ^[2] .

IC50 & Target

Kd: 1.6 μM (nucleocapsid protein) ^[2]

In Vitro

RSV604 (5 days) inhibits the growth of four laboratory strains of RSV (RSS, Long, A2 and B), with EC ₅₀ s ranging from 0.5 to 0.9 μM in plaque reduction assay ^[1] .
RSV604 (6 days) inhibits RSV-induced HEp-2 cell death, with an EC ₅₀ of 0.86 μM ^[1] .
RSV604 (3 days) reduces viral antigen synthesis in RSV-infected HEp-2 cells, with an EC ₅₀ of 1.7 μM ^[1] .
RSV604 (1-20 μM; 7 days) dose-dependently inhibits RSV infection in human airway epithelial (HAE) cells, with no gross cytotoxicity, leakage of basolateral fluid to the apical surface, or alteration of cilium beat frequency ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00416442	Novartis Pharmaceuticals\|Novartis	Healthy	October 2006	Phase 1
NCT00232635	Arrow Therapeutics	Respiratory Syncytial Virus Infections	September 2005	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 257.47 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.5747 mL	12.8737 mL	25.7473 mL
5 mM	0.5149 mL	2.5747 mL	5.1495 mL
10 mM	0.2575 mL	1.2874 mL	2.5747 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (6.44 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (6.44 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (6.44 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

Urea, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N′-(2-fluorophenyl)-

N-[(3S)-2,3-Dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N′-(2-fluorophenyl)urea

(S)-1-(2-Fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea

RSV 604

(S)-N-(2-Fluorophenyl)-N′-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea

1-(2-Fluorophenyl)-3-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]urea